Eurocine Vaccines AB
![Eurocine Vaccines AB](https://nordic-issuing.se/wp-content/uploads/a60ba14ebd18d5cb_org-e1646902085410.jpg)
4 Oct - 18 Oct 2022Rights issue
Eurocine Vaccines is a pharmaceutical company. The company develops vaccines with its own technology platform Endocine™, which are later licensed to partners for further development and commercialization. The development takes place in collaboration with other companies in the industry. The Endocine™ technology platform can also be offered to other companies for development within specific indications. The head office is in Solna.
Read more on the company's website
The offer in summary
Record date : 29 September 2022
Subscription period: 4 October - 18 October 2022
Subscription rights: Anyone who were shareholder in the Company on the record date of September 29, 2022 has a preferential right to subscribe for shares in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) subscription right. Five (5) subscription rights entitle to subscribe for three (3) new shares.
Subscription price: SEK 0.75
The offer: 10 421 943 shares which corresponds to ca MSEK 7.8
Trade with subscription rights: 4 October - 13 October 2022
Marketplace : Spotlight Stock Market
Financial advisor: Sedermera Corporate Finance
Subscribe directly via Nordnet here
Subscribe directly via Avanza here
![](https://nordic-issuing.se/wp-content/themes/nordic-issuing/img/inline/dot.png)